Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DEXAMETHASONE

All products: general benefit

Other products in the same Health Canada class (H02AB) — coverage varies; not interchangeable

  • Dexamethasone (Decadron): general benefit, Not a benefit
  • Hydrocortisone (Cortef): general benefit, Listing status unconfirmed
  • Methylprednisolone (Medrol): general benefit
  • Methylprednisolone (Depo-Medrol): general benefit
  • Prednisolone (Pediapred Oral Liquid): general benefit, Not a benefit
  • Prednisone (Winpred): general benefit, Not a benefit

3 more in the class list below

Apo-Dexamethasone · DIN 02261081 · 0.5mg · tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Dexamethasone · DIN 02261081 Manufacturer: Apotex Inc.; listing date 2005-04-28 Health Canada: Marketed since 2004-11-17 · brand APO-DEXAMETHASONE · ATC H02AB02 DEXAMETHASONE · form Tablet · route Oral · ingredients DEXAMETHASONE 0.5 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Dexamethasone: Formulary list price $0.1564/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1564 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74650 · Verify on the e-Formulary ↗ (DIN 02261081)

Source record
DIN 02261081: Apo-Dexamethasone Raw flags: sec3=Y Item: 680400022; group id 707; item number 1746; lccId None; manufacturer id APX Source form: Tab; strength: 0.5mg Recorded listing: General benefit Source prices (unrounded): $0.1564; ministry $0.1564 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02261081 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74650
Interchangeable products
Decadron · DIN 00016462 · not recorded PMS-Dexamethasone · DIN 01964976 · $0.1564
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (68:04 Corticosteroids) and how they are covered

Matched class: 68:04 Corticosteroids

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, CICLESONIDE, FLUDROCORTISONE ACETATE, FLUTICASONE FUROATE, FLUTICASONE PROPIONATE, METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, MOMETASONE FUROATE, TRIAMCINOLONE ACETONIDE Some products covered without a code (check the product listing): BUDESONIDE, DEXAMETHASONE 21-PHOSPHATE, HYDROCORTISONE, PREDNISOLONE SODIUM PHOSPHATE, PREDNISONE 68:04 Corticosteroids

DEXAMETHASONE 21-PHOSPHATE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 4mg/mL · Inj Sol

HYDROCORTISONE

· 5 products · General benefit (4), Temporary benefit (1) · strengths: 10mg, 20mg · Tab

METHYLPREDNISOLONE

· 1 products · General benefit · strengths: 4mg · Tab

METHYLPREDNISOLONE ACETATE

· 3 products · General benefit · strengths: 40mg/mL, 80mg/mL, 100mg/5mL · Inj Susp-1mL Pk, Inj Susp-5mL Pk

PREDNISOLONE SODIUM PHOSPHATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 6.7mg/5mL · O/L

PREDNISONE

· 7 products · General benefit (5), Listed, not a benefit (2) · strengths: 1mg, 5mg, 50mg · Tab

TRIAMCINOLONE ACETONIDE

· 3 products · General benefit · strengths: 40mg/mL, 50mg/5mL, 200mg/5mL · Inj Susp-1mL Pk, Inj Susp-5mL Pk

TRIAMCINOLONE HEXACETONIDE

· 1 products · Limited Use, codes 580 · strengths: 20mg/mL · 1mL-Amp Pk

FLUDROCORTISONE ACETATE

· 2 products · General benefit · strengths: 0.1mg · Tab

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 50mcg/Metered Dose, 100mcg/Metered Dose · Aero Inh-200 Dose Pk

BUDESONIDE

· 12 products · Limited Use, codes 260, 261, 262, 263, 264 (9), General benefit (3) · strengths: 0.125mg/mL, 0.25mg/mL, 0.5mg/mL, 100mcg/Metered Dose, 200mcg/Metered Dose, 400mcg/Metered Dose · Inh Susp, Pd Inh-200 Dose Pk

CICLESONIDE

· 3 products · General benefit · strengths: 100mcg/Actuation, 200mcg/Actuation, 50mcg/Actuation · Inh-120 Dose Pk, Metered Dose Nas Sp-120 Dose Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:04 and 5 more
Full class listing Related classes: 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS MAXIDEX® (dexamethasone ophthalmic ointment, USP and dexamethasone ophthalmic suspension, BP) is indicated for: • Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, iritis, cyclitis, and selected infective conjunctivitis when the inherit hazard of steroid use is acceptable to obtain an advisable diminution in edema and inflammation. • Corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. 1.1 Pediatrics Pediatrics (< 18 years of age): The safety and efficacy of MAXIDEX in children have not been established. 1.2 Geriatrics Geriatrics (> 60 years of age): No overall differences in safety or effectiveness have been observed between elderly and younger patients. https://pdf.hres.ca/dpd_pm/00072175.PDF PM date: April 01, 2001 Source product: MAXIDEX; DIN 00042560; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.